The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma

E. R. Simpson, B. Gallie, N. Laperrierre, A. Beiki-Ardakani, T. Kivelä, V. Raivio, J. Heikkonen, L. Desjardins, R. Dendale, A. Mazal, N. Bornfeld, W. Sauerwein, D. Flüehs, L. Brualla, S. G. Honavar, V. A. Reddy, S. Suzuki, N. Murakami, S. Saakyan, V. Valskiy & 26 others A. Amiryan, S. Seregard, C. All-Eriksson, L. Hjelmqvist, G. Lundell, G. Sinclair, M. Lundell, B. Damato, R. D. Errington, P. Mayles, H. Mayles, C. Bergstrom, H. Grossniklaus, I. Crocker, E. Butker, Matthew Wilson, B. Haik, H. Geischen, P. Patra, J. Duker, J. Mignano, M. Rivard, P. T. Finger, E. Semenova, W. Choi, N. I. Kalach

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Purpose: To present the American Brachytherapy Society (ABS) guidelines for plaque brachytherapy of choroidal melanoma and retinoblastoma. Methods and Materials: An international multicenter Ophthalmic Oncology Task Force (OOTF) was assembled to include 47 radiation oncologists, medical physicists, and ophthalmic oncologists from 10 countries. The ABS-OOTF produced collaborative guidelines, based on their eye cancer-specific clinical experience and knowledge of the literature. This work was reviewed and approved by the ABS Board of Directors as well as within the journal's peer-reivew process. Results: The ABS-OOTF reached consensus that ophthalmic plaque radiation therapy is best performed in subspecialty brachytherapy centers. Quality assurance, methods of plaque construction, and dosimetry should be consistent with the 2012 joint guidelines of the American Association of Physicists in Medicine and ABS. Implantation of plaque sources should be performed by subspecialty-trained surgeons. Although there exist select restrictions related to tumor size and location, the ABS-OOTF agreed that most melanomas of the iris, ciliary body, and choroid could be treated with plaque brachytherapy. The ABS-OOTF reached consensus that tumors with gross orbital extension and blind painful eyes and those with no light perception vision are unsuitable for brachytherapy. In contrast, only select retinoblastomas are eligible for plaque brachytherapy. Prescription doses, dose rates, treatment durations, and clinical methods are described. Conclusions: Plaque brachytherapy is an effective eye and vision-sparing method to treat patients with intraocular tumors. Practitioners are encouraged to use ABS-OOTF guidelines to enhance their practice.

Original languageEnglish (US)
Pages (from-to)1-14
Number of pages14
JournalBrachytherapy
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Retinoblastoma
Brachytherapy
Consensus
Guidelines
Advisory Committees
Uveal melanoma
Melanoma
Eye Neoplasms
Neoplasms
Ciliary Body
Choroid
Iris
Prescriptions
Radiotherapy
Joints

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Simpson, E. R., Gallie, B., Laperrierre, N., Beiki-Ardakani, A., Kivelä, T., Raivio, V., ... Kalach, N. I. (2014). The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy, 13(1), 1-14. https://doi.org/10.1016/j.brachy.2013.11.008

The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. / Simpson, E. R.; Gallie, B.; Laperrierre, N.; Beiki-Ardakani, A.; Kivelä, T.; Raivio, V.; Heikkonen, J.; Desjardins, L.; Dendale, R.; Mazal, A.; Bornfeld, N.; Sauerwein, W.; Flüehs, D.; Brualla, L.; Honavar, S. G.; Reddy, V. A.; Suzuki, S.; Murakami, N.; Saakyan, S.; Valskiy, V.; Amiryan, A.; Seregard, S.; All-Eriksson, C.; Hjelmqvist, L.; Lundell, G.; Sinclair, G.; Lundell, M.; Damato, B.; Errington, R. D.; Mayles, P.; Mayles, H.; Bergstrom, C.; Grossniklaus, H.; Crocker, I.; Butker, E.; Wilson, Matthew; Haik, B.; Geischen, H.; Patra, P.; Duker, J.; Mignano, J.; Rivard, M.; Finger, P. T.; Semenova, E.; Choi, W.; Kalach, N. I.

In: Brachytherapy, Vol. 13, No. 1, 01.01.2014, p. 1-14.

Research output: Contribution to journalArticle

Simpson, ER, Gallie, B, Laperrierre, N, Beiki-Ardakani, A, Kivelä, T, Raivio, V, Heikkonen, J, Desjardins, L, Dendale, R, Mazal, A, Bornfeld, N, Sauerwein, W, Flüehs, D, Brualla, L, Honavar, SG, Reddy, VA, Suzuki, S, Murakami, N, Saakyan, S, Valskiy, V, Amiryan, A, Seregard, S, All-Eriksson, C, Hjelmqvist, L, Lundell, G, Sinclair, G, Lundell, M, Damato, B, Errington, RD, Mayles, P, Mayles, H, Bergstrom, C, Grossniklaus, H, Crocker, I, Butker, E, Wilson, M, Haik, B, Geischen, H, Patra, P, Duker, J, Mignano, J, Rivard, M, Finger, PT, Semenova, E, Choi, W & Kalach, NI 2014, 'The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma', Brachytherapy, vol. 13, no. 1, pp. 1-14. https://doi.org/10.1016/j.brachy.2013.11.008
Simpson, E. R. ; Gallie, B. ; Laperrierre, N. ; Beiki-Ardakani, A. ; Kivelä, T. ; Raivio, V. ; Heikkonen, J. ; Desjardins, L. ; Dendale, R. ; Mazal, A. ; Bornfeld, N. ; Sauerwein, W. ; Flüehs, D. ; Brualla, L. ; Honavar, S. G. ; Reddy, V. A. ; Suzuki, S. ; Murakami, N. ; Saakyan, S. ; Valskiy, V. ; Amiryan, A. ; Seregard, S. ; All-Eriksson, C. ; Hjelmqvist, L. ; Lundell, G. ; Sinclair, G. ; Lundell, M. ; Damato, B. ; Errington, R. D. ; Mayles, P. ; Mayles, H. ; Bergstrom, C. ; Grossniklaus, H. ; Crocker, I. ; Butker, E. ; Wilson, Matthew ; Haik, B. ; Geischen, H. ; Patra, P. ; Duker, J. ; Mignano, J. ; Rivard, M. ; Finger, P. T. ; Semenova, E. ; Choi, W. ; Kalach, N. I. / The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. In: Brachytherapy. 2014 ; Vol. 13, No. 1. pp. 1-14.
@article{2bd16756992a472fa0d23178a36279d4,
title = "The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma",
abstract = "Purpose: To present the American Brachytherapy Society (ABS) guidelines for plaque brachytherapy of choroidal melanoma and retinoblastoma. Methods and Materials: An international multicenter Ophthalmic Oncology Task Force (OOTF) was assembled to include 47 radiation oncologists, medical physicists, and ophthalmic oncologists from 10 countries. The ABS-OOTF produced collaborative guidelines, based on their eye cancer-specific clinical experience and knowledge of the literature. This work was reviewed and approved by the ABS Board of Directors as well as within the journal's peer-reivew process. Results: The ABS-OOTF reached consensus that ophthalmic plaque radiation therapy is best performed in subspecialty brachytherapy centers. Quality assurance, methods of plaque construction, and dosimetry should be consistent with the 2012 joint guidelines of the American Association of Physicists in Medicine and ABS. Implantation of plaque sources should be performed by subspecialty-trained surgeons. Although there exist select restrictions related to tumor size and location, the ABS-OOTF agreed that most melanomas of the iris, ciliary body, and choroid could be treated with plaque brachytherapy. The ABS-OOTF reached consensus that tumors with gross orbital extension and blind painful eyes and those with no light perception vision are unsuitable for brachytherapy. In contrast, only select retinoblastomas are eligible for plaque brachytherapy. Prescription doses, dose rates, treatment durations, and clinical methods are described. Conclusions: Plaque brachytherapy is an effective eye and vision-sparing method to treat patients with intraocular tumors. Practitioners are encouraged to use ABS-OOTF guidelines to enhance their practice.",
author = "Simpson, {E. R.} and B. Gallie and N. Laperrierre and A. Beiki-Ardakani and T. Kivel{\"a} and V. Raivio and J. Heikkonen and L. Desjardins and R. Dendale and A. Mazal and N. Bornfeld and W. Sauerwein and D. Fl{\"u}ehs and L. Brualla and Honavar, {S. G.} and Reddy, {V. A.} and S. Suzuki and N. Murakami and S. Saakyan and V. Valskiy and A. Amiryan and S. Seregard and C. All-Eriksson and L. Hjelmqvist and G. Lundell and G. Sinclair and M. Lundell and B. Damato and Errington, {R. D.} and P. Mayles and H. Mayles and C. Bergstrom and H. Grossniklaus and I. Crocker and E. Butker and Matthew Wilson and B. Haik and H. Geischen and P. Patra and J. Duker and J. Mignano and M. Rivard and Finger, {P. T.} and E. Semenova and W. Choi and Kalach, {N. I.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.brachy.2013.11.008",
language = "English (US)",
volume = "13",
pages = "1--14",
journal = "Brachytherapy",
issn = "1538-4721",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma

AU - Simpson, E. R.

AU - Gallie, B.

AU - Laperrierre, N.

AU - Beiki-Ardakani, A.

AU - Kivelä, T.

AU - Raivio, V.

AU - Heikkonen, J.

AU - Desjardins, L.

AU - Dendale, R.

AU - Mazal, A.

AU - Bornfeld, N.

AU - Sauerwein, W.

AU - Flüehs, D.

AU - Brualla, L.

AU - Honavar, S. G.

AU - Reddy, V. A.

AU - Suzuki, S.

AU - Murakami, N.

AU - Saakyan, S.

AU - Valskiy, V.

AU - Amiryan, A.

AU - Seregard, S.

AU - All-Eriksson, C.

AU - Hjelmqvist, L.

AU - Lundell, G.

AU - Sinclair, G.

AU - Lundell, M.

AU - Damato, B.

AU - Errington, R. D.

AU - Mayles, P.

AU - Mayles, H.

AU - Bergstrom, C.

AU - Grossniklaus, H.

AU - Crocker, I.

AU - Butker, E.

AU - Wilson, Matthew

AU - Haik, B.

AU - Geischen, H.

AU - Patra, P.

AU - Duker, J.

AU - Mignano, J.

AU - Rivard, M.

AU - Finger, P. T.

AU - Semenova, E.

AU - Choi, W.

AU - Kalach, N. I.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose: To present the American Brachytherapy Society (ABS) guidelines for plaque brachytherapy of choroidal melanoma and retinoblastoma. Methods and Materials: An international multicenter Ophthalmic Oncology Task Force (OOTF) was assembled to include 47 radiation oncologists, medical physicists, and ophthalmic oncologists from 10 countries. The ABS-OOTF produced collaborative guidelines, based on their eye cancer-specific clinical experience and knowledge of the literature. This work was reviewed and approved by the ABS Board of Directors as well as within the journal's peer-reivew process. Results: The ABS-OOTF reached consensus that ophthalmic plaque radiation therapy is best performed in subspecialty brachytherapy centers. Quality assurance, methods of plaque construction, and dosimetry should be consistent with the 2012 joint guidelines of the American Association of Physicists in Medicine and ABS. Implantation of plaque sources should be performed by subspecialty-trained surgeons. Although there exist select restrictions related to tumor size and location, the ABS-OOTF agreed that most melanomas of the iris, ciliary body, and choroid could be treated with plaque brachytherapy. The ABS-OOTF reached consensus that tumors with gross orbital extension and blind painful eyes and those with no light perception vision are unsuitable for brachytherapy. In contrast, only select retinoblastomas are eligible for plaque brachytherapy. Prescription doses, dose rates, treatment durations, and clinical methods are described. Conclusions: Plaque brachytherapy is an effective eye and vision-sparing method to treat patients with intraocular tumors. Practitioners are encouraged to use ABS-OOTF guidelines to enhance their practice.

AB - Purpose: To present the American Brachytherapy Society (ABS) guidelines for plaque brachytherapy of choroidal melanoma and retinoblastoma. Methods and Materials: An international multicenter Ophthalmic Oncology Task Force (OOTF) was assembled to include 47 radiation oncologists, medical physicists, and ophthalmic oncologists from 10 countries. The ABS-OOTF produced collaborative guidelines, based on their eye cancer-specific clinical experience and knowledge of the literature. This work was reviewed and approved by the ABS Board of Directors as well as within the journal's peer-reivew process. Results: The ABS-OOTF reached consensus that ophthalmic plaque radiation therapy is best performed in subspecialty brachytherapy centers. Quality assurance, methods of plaque construction, and dosimetry should be consistent with the 2012 joint guidelines of the American Association of Physicists in Medicine and ABS. Implantation of plaque sources should be performed by subspecialty-trained surgeons. Although there exist select restrictions related to tumor size and location, the ABS-OOTF agreed that most melanomas of the iris, ciliary body, and choroid could be treated with plaque brachytherapy. The ABS-OOTF reached consensus that tumors with gross orbital extension and blind painful eyes and those with no light perception vision are unsuitable for brachytherapy. In contrast, only select retinoblastomas are eligible for plaque brachytherapy. Prescription doses, dose rates, treatment durations, and clinical methods are described. Conclusions: Plaque brachytherapy is an effective eye and vision-sparing method to treat patients with intraocular tumors. Practitioners are encouraged to use ABS-OOTF guidelines to enhance their practice.

UR - http://www.scopus.com/inward/record.url?scp=84892503158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892503158&partnerID=8YFLogxK

U2 - 10.1016/j.brachy.2013.11.008

DO - 10.1016/j.brachy.2013.11.008

M3 - Article

VL - 13

SP - 1

EP - 14

JO - Brachytherapy

JF - Brachytherapy

SN - 1538-4721

IS - 1

ER -